Stock Market News2 weeks Denali Q4 Earnings Beat Estimates, Hunter Syndrome Drug in Focus Zacks
DNLI reports a narrower-than-expected loss for the fourth quarter of 2024. Denali remains on track to submit a BLA for tividenofusp alfa for the treatment of MPS II (Hunter syndrome).
X